REFERENCES
- Black J W, Leff P. Operational models of pharmacological agonists. Proc Soc Lond Biol 1983; 220: 141–162, [CSA]
- Samama P, Cotecchia S, Costa T, Lefkowitz R J. A mutation-induced activated state of the β2-adrenergic receptor: Extending the ternary complex model. J Biol Chem 1993; 268: 4625–4636, [INFOTRIEVE], [CSA]
- Weiss J M, Morgan P H, Lutz M W, Kenakin T P. The cubic ternary complex receptor-occupancy model. I. Model description. J Theor Biol 1996; 178: 151–167, [CSA], [CROSSREF]
- Weiss J M, Morgan P H, Lutz M W, Kenakin T P. The cubic ternary complex receptor-occupancy model. II. Understanding apparent affinity J Theor Biol 1996; 178: 169–182, [CSA]
- Weiss J M, Morgan P H, Lutz M W, Kenakin T P. The cubic ternary complex receptor-occupancy model. III. Resurrecting Efficacy. J Theor Biol 1996; 181: 381–397, [INFOTRIEVE], [CSA], [CROSSREF]
- Gaddum J H. The quantitative effects of antagonistic drugs. J Physiol Lond 1937; 89: 7P–9P, [CSA]
- Arunlakshana O, Schild H O. Some quantitative uses of drug antagonists. Br J Pharmacol 1959; 14: 48–58, [CSA]
- Stone M, Angus J A. Developments of computer-based estimation of pA2 values and associated analysis. J Pharmacol Exp Ther 1978; 207: 705–718, [INFOTRIEVE], [CSA]
- Lew M J, Angus J A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 1996; 16: 328–337, [CSA], [CROSSREF]
- Ehlert F J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 1988; 33: 187–194, [INFOTRIEVE], [CSA]
- Christopolous A, Kenakin T P. G-protein coupled receptor allosterism and complexing. Pharmacol Rev 2002; 54: 323–374, [CSA], [CROSSREF]
- Stephenson R P. A modification of receptor theory. Br J Pharmacol 1956; 11: 379–393, [CSA]
- Kaumann A J, Marano M. On equilibrium dissociation constants for complexes of drug receptor subtypes. Selective and non-selective interactions of partial agonists with two β-adrenoceptor subtypes mediating positive chronotropic effects of (-) isoprenaline in kitten atria. Naunyn Schmiedebeberg's Arch Pharmacol 1982; 219: 216–221, [CSA], [CROSSREF]
- Paton W DM, Rang H P. The uptake of atropine and related drugs by intestinal smooth muscle of the guinea pig in relation to acetylcholine receptors. Proc R Soc Lond Biol 1965; 163: 1–44, [INFOTRIEVE], [CSA]
- Gaddum J H, Hameed K A, Hathway D E, Stephens F F. Quantitative studies of antagonists for 5-hydroxytryptamine. Q J Exp Physiol 1955; 40: 49–74, [CSA]
- Jakubic J, Bacakova L, Lisa V, El-Fakahany E E, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997; 52: 172–179, [CSA]
- Maeda K, Nakata H, Koh Y, Miyakawa T, Ogata H, Takaoka Y, Sbibayama S, Sagawa K, Fukushima D, Moravek J, et al. Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitro. J Virol 2004; 78: 8654–8662, [INFOTRIEVE], [CSA], [CROSSREF]
- Watson C, Jenkinson S, Kazmierski W, Kenakin T P. The CCR5 Receptor-based mechanism of action of 873140, a potent allosteric non-competitive HIV entry-inhibitor. Mol Pharmacol 2005; 67: 1268–1282, [INFOTRIEVE], [CSA], [CROSSREF]